問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberADCT-402-107(LOTIS-10)

2023-01-23 - 2027-10-13

Phase I

Recruiting2

ICD-10C83.38

Diffuse large B-cell lymphoma, lymph nodes of multiple sites

ICD-10C84.68

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites

ICD-10C84.78

Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites

ICD-10C85.20

Mediastinal (thymic) large B-cell lymphoma, unspecified site

ICD-10C85.21

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck

ICD-10C85.22

Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes

ICD-10C85.23

Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes

ICD-10C85.24

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb

ICD-10C85.25

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb

ICD-10C85.26

Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes

ICD-10C85.27

Mediastinal (thymic) large B-cell lymphoma, spleen

ICD-10C85.28

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites

ICD-10C85.29

Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9200.08

Reticulosarcoma, lymph nodes of multiple sites

  • Trial Applicant

    Pharmaceutical Research Associates Taiwan Inc.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/20

Investigators and Locations

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 譚傳德

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    9 participants

  • Global

    56 participants